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To determine the prevalence and genotypes of extended-spectrum beta-lactamases (ESBLs) among clinical
isolates of Klebsiella pneumoniae and Escherichia coli, we performed antibiotic susceptibility testing, pI deter-
mination, induction testing, transconjugation, and DNA sequencing analysis. Among the 509 isolates collected
from 13 university hospitals in Korea, 39.2% produced ESBLs. ESBL-producing isolates were detected in every
region in Korea. A total of 44.6% of the isolates produced both TEM- and SHV-type ESBLs, and 52% of
ESBL-producing isolates transferred resistance to ceftazidime by transconjugation. The ESBLs were TEM-19,
TEM-20, TEM-52, SHV-2a, SHV-12, and one new variant identified for the first time in Korea, namely,
TEM-116. TEM-1 and SHV-12 were by far the most common variants. TEM-1, TEM-116, and SHV-12 showed
a high prevalence in K. pneumoniae. Two isolates (E. coli SH16 and K. pneumoniae SV3) produced CMY-1-like
beta-lactamases, which play a decisive role in resistance to cefoxitin and cefotetan, as well as TEM-type
enzymes (TEM-20 and TEM-52, respectively). Using MIC patterns and DNA sequencing analysis, we postu-
lated a possible evolution scheme among TEM-type beta-lactamases in Korea: from TEM-1 to TEM-19, from
TEM-19 to TEM-20, and from TEM-20 to TEM-52.
The beta-lactamases (EC 3.5.2.6) produced by bacteria are
known to protect against the lethal effect of penicillins, ceph-
alosporins, or monobactams on cell wall synthesis. The pro-
duction of beta-lactamase is the single most prevalent mecha-
nism responsible for resistance to beta-lactams among clinical
isolates of the family Enterobacteriaceae (23). A variety of
beta-lactamases have been classified into classes A, B, C, and
D according to their amino acid homology (3). Extended-
spectrum beta-lactamases (ESBLs) are clavulanate-susceptible
enzymes conferring broad resistance to penicillins, aztreonam,
and cephalosporins (with the exception of cephamycins) and
are detected most commonly in Klebsiella pneumoniae and
Escherichia coli (15). ESBLs are often plasmid mediated, and
most are mutants of the classic TEM and SHV enzymes (class
A), with one or more amino acid substitutions around the
active site (19). These changes allow hydrolysis of extended-
spectrum cephalosporins (e.g., ceftazidime and cefotaxime)
and monobactams (e.g., aztreonam), which are stable to classic
TEM and SHV enzymes (5). AmpC beta-lactamases, mostly
conferring resistance to many beta-lactam antibiotics (cepha-
mycins and extended-spectrum cephalosporins), are included
in the class C beta-lactamases. Plasmid-mediated AmpC beta-
lactamases are often expressed in large amounts and can pose
therapeutic problems (16). Plasmid-mediated AmpC beta-lac-
tamases have been recently reported for K. pneumoniae
(CMY-1, CMY-2, CMY-8, MOX-1, MOX-2, FOX-1, FOX-5,
LAT-1, LAT-2, LAT-2b, ACT-1, MIR-1, and ACC-1), Kleb-
siella oxytoca (CMY-5 and FOX-3), E. coli (CMY-4, CMY-6,
CMY-7, CMY-9, FOX-2, FOX-4, BIL-1, LAT-3, and LAT-4),
Salmonella enterica serovar Enteritidis (DHA-1), Pseudomonas
mirabilis (CMY-3), and S. enterica serovar Senftenberg (CMY-
2b) (12). In view of the risk of spreading of ESBL and AmpC
resistance determinants among enterobacterial isolates, it is
important to elucidate the mechanism of resistance in isolates
that are resistant to extended-spectrum beta-lactams. The
present study was conducted to determine the prevalence and
genotypes of ESBLs and AmpC beta-lactamases among clini-
cal isolates of K. pneumoniae and E. coli in Korea. We inves-
tigated the interrelationships of the TEM-type beta-lactama-
ses, paying particular attention to the evolution of the enzymes
in Korea.
MATERIALS AND METHODS
Bacterial strains. A total of 9,219 clinical isolates of K. pneumoniae (2,652)
and E. coli (6,567) were isolated from April to June 2002 in 13 hospitals in six
different regions, including all representative cities, in Korea (Fig. 1). Approxi-
mately 40 isolates per hospital, collected from sporadic cases in the intensive care
unit and the medical, surgical, and pediatric wards, were selected for determining
the prevalence of ESBL-producing strains. The isolates were identified by using
conventional techniques (6) and/or the Vitek GNI card (bioMe´rieux Vitek Inc.,
Hazelwood, Mo.). E. coli J53 AzideR (11) was used as the recipient strain for
transfer by transconjugation. E. coli ATCC 25922 was used as the MIC reference
strain.
Susceptibility to beta-lactams. Antibiotic susceptibility was determined by disk
diffusion tests that were performed according to the recommendations of the
National Committee for Clinical Laboratory Standards (17) with BBL (Cock-
eysville, Md.) disks impregnated with ampicillin, ampicillin-sulbactam, cephalo-
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thin, cefoxitin, cefotetan, ceftazidime, cefotaxime, cefepime, aztreonam, and
imipenem. Disks were dispensed with a BBL Sensi-Disk 12-place dispenser. The
putative ESBL-producing strains were tested by the clavulanate double-disk
potentiation procedure of Jarlier et al. (10). In this test, a plate was inoculated
as described above for a standard disk diffusion test. Disks containing aztreonam
and extended-spectrum cephalosporins (cefotaxime and ceftazidime) were then
placed 20 mm (center to center) from an ampicillin-clavulanic acid disk (20/10
g; BBL) prior to incubation. After overnight incubation at 37°C, the production
of an ESBL by the test organism was inferred by the presence of characteristic
distortions of the inhibition zones indicative of clavulanate potentiation of the
activity of the test drug. MICs were determined on Muller-Hinton agar plates
(Difco Laboratories, Detroit, Mich.) containing serially twofold-diluted beta-
lactams as previously described (12).
Transconjugation experiments. Transconjugation experiments were per-
formed as described previously (12) with sodium azide-resistant E. coli J53
AzideR as the recipient. Transconjugants were selected on Muller-Hinton agar
supplemented with sodium azide (Sigma, Louis, Mo.) (150 mg/liter) to inhibit the
growth of the donor strain and with ceftazidime (1 mg/liter) or cefoxitin (20
mg/liter) to inhibit the growth of the recipient strain. Ceftazidime and cefoxitin
were used for the transfer of ESBL and AmpC beta-lactamase genes, respec-
tively.
IEF analysis. Crude bacterial extracts were obtained from transconjugants
after centrifugation of sonicated culture as previously described (12). Sonic
extracts were used for the determination of isoelectric points and beta-lactamase
activity. Isoelectric focusing (IEF) was performed in Ready Gel precast IEF
polyacrylamide gels (Bio-Rad, Hercules, Calif.) as previously described (12).
Gels were developed with 0.5 mM nitrocefin (Oxoid, Basingstoke, United King-
dom). Inducibility of AmpC beta-lactamases was inferred from the intensity of
IEF patterns for beta-lactamase extracts induced and uninduced by cefoxitin (50
mg/liter), as recommended by Pitout et al. (21). The beta-lactamase activities
were determined for the diverse substrates by a spectrophotometric method (16)
in 50 mM sodium phosphate (pH 7.0) at 37°C on a spectrophotometer (UV-160;
Shimadzu, Kyoto, Japan). One unit was the amount of enzyme hydrolyzing 1
nmol of substrate per min at pH 7.0 and 37°C. The protein concentration was
measured by the Bradford dye-binding procedure with the Bio-Rad protein
assay, with bovine serum albumin (Sigma) as a standard.
PCR amplification and DNA sequencing. The primers for PCR amplification
were designed by selecting consensus sequences in a multiple-nucleotide align-
ment of 60 TEM-type beta-lactamase genes (blaTEM), 27 SHV-type beta-lacta-
mase genes (blaSHV), and 5 CMY-type beta-lactamase genes (blaCMY) by using
the Primer Calculator program (Williamstone Enterprises, Waltham, Mass.).
The primers were described previously (13): T1, T2, T3, and T4 were used for
blaTEM; S1, S2, S3, and S4 were used for blaSHV; and C1, C2, C3, and C4 were
used for blaCMY. The templates for PCR amplification in clinical isolates and
transconjugants were a whole-cell lysate and a plasmid preparation, respectively.
PCR amplifications were carried out as described previously (13). DNA sequenc-
ing was performed by the direct sequencing method with an automatic sequencer
(model 373A; Applied Biosystems, Weiterstadt, Germany), as previously de-
scribed (14). DNA sequence analysis was performed with DNASIS for Windows
(Hitachi Software Engineering America Ltd., San Bruno, Calif.). Database sim-
ilarity searches for both the nucleotide sequences and deduced protein se-
quences were performed with BLAST at the National Center for Biotechnology
Information website (http://www.ncbi.nlm.nih.gov).
Nucleotide sequence accession number. The blaTEM-116 gene nucleotide se-
quence appear in the GenBank nucleotide sequence database under accession
number AY425988.
RESULTS AND DISCUSSION
Prevalence of ESBL producers among K. pneumoniae and E.
coli isolates. The susceptibilities of a total of 9,219 clinical
FIG. 1. Map showing sites in the study, with the numbers of ESBL-producing isolates at each site in parentheses. Six hospitals (HJ, ND, SL,
SM, SS, and SV) were in Seoul. F, E. coli; Œ, K. pneumoniae; AJ, Ajou University Hospital; BD, BunDang Cha Medical Center; HJ, Asan Medical
Center; JN, Chonnam National University Hospital; KS, Kosin University Gospel Hospital; KY, KonYang University Hospital; ND, NeoDin Inc.;
SH, SuonChunHyang University Gumi Hospital; SL, Seoul National University Hospital; SM, Kangnam St. Mary’s Hospital; SS, Kangnam Sacred
Heart Hospital; SV, Sinchon Severance Hospital; WJ, Wonju Christian Hospital.
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isolates of K. pneumoniae and E. coli to beta-lactams were
tested in 13 hospitals in Korea. Strains resistant to ceftazidime,
cefotaxime, and aztreonam were more predominant in K.
pneumoniae (29, 32, and 29%, respectively) than in E. coli (11,
13, and 14%, respectively). Resistance to cefoxitin in K. pneu-
moniae (24%) and E. coli (14%) was higher than that to ce-
fotetan in K. pneumoniae (16%) and E. coli (5%). Resistance
to imipenem was not detected in either species (data not
shown). The prevalence of resistance to extended-spectrum
cephalosporins in 9,219 clinical isolates is similar to that re-
ported from Thailand (4) but is much higher than that in
European countries (9). A total of 509 randomly selected iso-
lates that were resistant to extended-spectrum cephalosporins
were studied by the double-disk test. The prevalence of ESBL-
producing strains was 30% in K. pneumoniae (78 of 260) and
9.2% in E. coli (23 of 249). ESBL-producing strains were de-
tected in every region in Korea and mainly in Seoul, the me-
tropolis of Korea. They were isolated in the greatest numbers
from two hospitals (KY and SH) (Fig. 1). A total of 19.8% of
the strains produced ESBLs. The prevalence of ESBL-produc-
ing strains in Korea was much higher than that in The Neth-
erlands, where approximately 2% of isolates produced ESBLs
(24). The clinical significance of these isolates, which were
widespread in Korea, is of great importance, as clinicians are
advised against the use of extended-spectrum cephalosporins,
aztreonam, and cephamycins.
Diversity of TEM- and SHV-type ESBLs. Ceftazidime resis-
tance was transferred from 42 of the 78 K. pneumoniae isolates
and from 14 of 23 E. coli isolates to the E. coli J53 AzideR
recipient. Taking into account the resistance phenotypes of
these strains, the resistance genotypes of 56 strains were ana-
lyzed by direct sequencing of the PCR-amplified blaTEM and
blaSHV genes. Only one large open reading frame was found,
which corresponds to a putative protein of 286 amino acids for
TEM-type or SHV-type beta-lactamase. Five different TEM-type
(blaTEM-1, blaTEM-19, blaTEM-20, blaTEM-52, and blaTEM-116)
and two different SHV-type (blaSHV-2a and blaSHV-12)
beta-lactamase sequences were found (Table 1). Table 1 shows
the prevalence and diversity of TEM- and SHV-type ESBL
determinants in different strains. Genes encoding TEM-type
ESBLs were detected in 17 isolates among 46 isolates produc-
ing TEM-type beta-lactamases and included genes for the fol-
lowing variants: TEM-19, TEM-20, TEM-52, and one new
variant, TEM-116, which was detected for first time in this
survey. Nineteen isolates among the remaining 29 isolates pro-
duced both TEM-1 and SHV-type ESBLs (Table 1). The re-
maining 10 isolates among the 29 isolates consisted of 7 K.
pneumoniae and 3 E. coli isolates. One of the seven K. pneu-
moniae isolates produced both TEM-1 and TEM-19, and six of
the seven K. pneumoniae isolates produced TEM-1, TEM-116,
and SHV-12. Thus, seven K. pneumoniae isolates produce an
ESBL(s). One of the three E. coli isolates produced both
TEM-1 and TEM-52, and one produced both TEM-1 and
TEM-116. Two of the three E. coli isolates produced TEM-
type ESBL. One of the three E. coli isolates may produce
another ESBL (e.g., CTX-M type), which was not determined
in this study, or may be false positive in ESBL activity (data not
shown). SHV-2a and SHV-12 ESBLs were detected in 2 and 32
isolates, respectively. Twenty-five isolates produced both
TEM- and SHV-type beta-lactamases. TEM-1 and SHV-12
were by far the most common variants. TEM-1, TEM-116, and
SHV-12 showed an especially high prevalence in K. pneu-
moniae. TEM-1 and SHV-12 were found in all of the hospitals,
while the less prevalent variants (TEM-19, TEM-20, TEM-52,
and SHV-2a) had a more restricted distribution. Except for
TEM-116, these results are similar to those reported from Italy
(20).
Properties of five representative ESBL-producing isolates.
Five representatives of 56 clinical isolates having the capacity
for transferring resistance to ceftazidime produced five differ-
ent TEM-type beta-lactamase variants (TEM-1, TEM-19,
TEM-20, TEM-52, and TEM-116). The beta-lactam MICs and
isoelectric points (pIs) for five representative isolates (SH8,
SL13, SH16, SV3, and SV10) are shown in Table 2. Five
transconjugants (Table 2) resulted from the transconjugation
experiment with ceftazidime selection. All isolates and their
transconjugants (except for trcSH8, producing TEM-1) were
resistant to ampicillin, cephalothin, ceftazidime, and aztreo-
nam. Resistance to cefotaxime (MIC of 64 mg/liter) was
observed in three isolates (SH16, SV3, and SV10) and their
transconjugants. Two isolates (SH16 and SV3) were resistant
to cefoxitin and cefotetan, and their transconjugants were sen-
sitive to them. trcSH16 and trcSV3 produced beta-lactamases
with a pI of 5.4, and SH16 and SV3 produced enzymes with pIs
of 5.4 and 8.0, respectively. On the basis of the pIs of the
beta-lactamases, their profiles of inhibition by ampicillin or
sulbactam, and DNA sequencing, the beta-lactamases with a pI
of 5.4 were TEM-1, TEM-19, TEM-20, and TEM-116. The
TABLE 1. Prevalence of TEM- and SHV-type beta-lactamases in 56 isolates of K. pneumoniae and E. coli with the capacity for transferring
resistance to ceftazidime
Species (no. of isolates)
No. of isolates producing the following beta-lactamasea:
TEM- type SHV- type
TEM-1 TEM-19 TEM-20 TEM-52 TEM-116 SHV-2a SHV-12
K. pneumoniae (42) 20 (13) 2 1b 10 (6) 2 (1) 25 (18)
E. coli (14) 9 (6) 1c 1 2 7 (6)
Total TEM type (46) 29 (19) [63.0] 2 [4.3] 1 [2.2] 2 [4.3] 12 (6) [26.1]
Total SHV type (34) 2 (1) [5.9] 32 (24) [94.1]
a The number of isolates that produced both TEM- and SHV-type beta-lactamases is in parentheses. The percentage of the total is in brackets.
b Isolate K. pneumoniae SV3, which produces both TEM- and CMY-type beta-lactamases.
c Isolate E. coli SH16, which produces both TEM- and CMY-type beta-lactamases.
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enzymes with pIs of 5.9, 8.0, and 8.2 were TEM-52, a CMY-
type beta-lactamase, and SHV-12, respectively. These beta-
lactamases had the same pIs as previously reported (1, 2, 7, 18).
Partial DNA sequences of the PCR products amplified with
CMY-specific primers (C1-C2 and C3-C4 primer pairs) and
whole-cell lysates of two isolates (SH16 and SV3) as templates
had very high homology with the gene for CMY-1. The beta-
lactam (especially, cephamycin) resistance phenotype of the
two isolates was similar to that of K. pneumoniae CHO (1),
which produces the enzyme CMY-1 and is resistant to cefoxitin
and cefotetan. CMY-1 (1) was firstly identified in Korea. The
CMY-type beta-lactamases of these two isolates (SH16 and
SV3) were not induced by cefoxitin. Their blaCMY genes were
transferred to the E. coli J53 AzideR recipient in a transcon-
jugation experiment (with cefoxitin at 20 mg/liter). These re-
sults indicated that the blaCMY genes of the two isolates are
plasmid-mediated genes. Because of the presence of CMY-
type beta-lactamase, the MICs of ampicillin-sulbactam, cefox-
itin, and cefotetan for SH16 and SV3 were increased relative to
those for trcSH16 and trcSV3, which produce TEM-20 and
TEM-52, respectively. The MIC of ampicillin was not reduced
by sulbactam in trcSH16 and trcSV3, which likely corresponds
to MIC patterns of strains producing Bush group 1 (class C)
AmpC beta-lactamases (3). SH8, which produces both SHV-12
and TEM-1, showed ESBL activity, while trcSH8, which does
not produce SHV-12 but produces TEM-1, did not show ESBL
activity. This suggests that the ESBL activity of SH8 is caused
by the presence of SHV-12.
In vivo evolution of TEM-type beta-lactamases. The MICs
of ceftazidime, cefotaxime, and aztreonam for trcSH16, which
produces TEM-20, were two- or fourfold greater than the
corresponding MICs for trcSL13, which produces TEM-19,
and similar to those for trcSV10, which produces TEM-116.
The MICs of ceftazidime, cefotaxime, and aztreonam for
trcSV3, which produces TEM-52, were twofold greater than
the corresponding MICs for trcSH16, which produces TEM-20
(Table 2). These results were similar to those previously ob-
tained by in vitro mutagenesis of TEM-1 (8). The activities of
TEM-19, TEM-20, TEM-52, and TEM-116 in their respective
producers were determined. The specific activities (in units per
milligram of protein) of crude bacterial extracts of trcSL13,
trcSH16, trcSV3, and trcSV10 against ceftazidime, cefotaxime,
and aztreonam were as follows: 85 (ceftazidime), 99 (cefo-
taxime), and 3.1 (aztreonam) for TEM-19; 221 (ceftazidime),
216 (cefotaxime), and 4.4 (aztreonam) for TEM-20; 439 (cefta-
zidime), 452 (cefotaxime), and 7.6 (aztreonam) for TEM-52;
and 216 (ceftazidime), 112 (cefotaxime), and 3.4 (aztreonam)
for TEM-116. These results supported MIC patterns of cefta-
zidime, cefotaxime, and aztreonam for four transconjugants
(MICs for trcSL13 or trcSV10  MICs for trcSH16  MICs
for trcSV3) and indicated that TEM-116 works as an ESBL.
These results also appear to represent the in vivo evolution of
TEM-type beta-lactamase genes (blaTEM-1 3 blaTEM-19 3
blaTEM-20 3 blaTEM-52) under the selective pressure of anti-
microbial therapy (especially ceftazidime, cefotaxime, and aztreo-
nam), as was the case with blaSHV-8 (22). The in vivo evolution
pathway was confirmed with the sequence data for TEM-type
beta-lactamases. The deduced amino acid sequence of TEM-19
had one amino acid substitution compared to that of TEM-1
(Gly-2383Ser), TEM-20 differed from TEM-19 by one amino
acid at position 182 (Met-1823Thr), and TEM-52 differed
from TEM-20 by one amino acid at position 104 (Glu-
1043Lys) (Table 3). TEM-1, TEM-19, TEM-20, and TEM-52
are the TEM-type beta-lactamases identified in Korea to date.
These findings indicated that TEM-1 developed into TEM-19,
that TEM-19 evolved into TEM-20, and that TEM-20 evolved
into TEM-52. TEM-116 was first and most prevalently identi-
fied in Korea. The amino acid replacements at position 84 and
184 have not been observed in other TEM-type beta-lactama-
ses. In order to find out whether there is a functional advantage
in such changes, we will try to analyze the biochemical char-
acteristics of TEM-116. The MIC patterns of five transconju-
gants and DNA sequence analysis results indicated that there
might be two schemes for in vivo evolution: (i) from TEM-1 to
TABLE 2. Profiles of representative ESBL-producing strains isolated from a Korean nationwide survey in 2002 and their
transconjugants (trc)
Strain Species Type ofspecimen
MIC (g/ml) of the following beta-lactama:
pI(s) Beta-lactamase(s)
AMP A/S CEP FOX CTT CAZ CTX FEP AZT IMP
SH8 K. pneumoniae Urine 256 16/8 128 4 0.25 32 4 0.5 32 0.125 5.4, 8.2 TEM-1, SHV-12
trcSH8 256 16/8 16 2 0.125 2 0.5 0.0625 1 0.0625 5.4 TEM-1
SL13 K. pneumoniae Urine 256 16/8 256 4 0.25 32 16 4 32 0.125 5.4 TEM-19
trcSL13 256 16/8 128 4 0.25 32 16 2 32 0.125 5.4 TEM-19
SH16 E. coli Sputum 256 128/64 256 256 64 64 64 4 64 0.25 5.4, 8.0 TEM-20, CMY type
trcSH16 256 16/8 256 2 0.25 64 64 2 64 0.125 5.4 TEM-20
SV3 K. pneumoniae Urine 256 128/64 256 256 128 128 128 4 256 0.25 5.9, 8.0 TEM-52, CMY type
trcSV3 256 16/8 256 4 0.25 128 128 2 128 0.25 5.9 TEM-52
SV10 E. coli Urine 256 16/8 256 4 0.25 64 64 2 64 0.25 5.4 TEM-116
trcSV10 256 16/8 256 2 0.25 64 32 1 32 0.125 5.4 TEM-116
J53AzideR E. coli 4 4/2 4 2 0.0625 0.125 0.0625 0.0625 0.0625 0.0625
a Abbreviations: AMP, ampicillin; A/S, ampicillin-sulbactam (2:1); CEP, cephalothin; FOX, cefoxitin; CTT, cefotetan; CAZ, ceftazidime; CTX, cefotaxime; FEP,
cefepime; AZT, aztreonam; IMP, imipenem.
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TEM-19, from TEM-19 to TEM-20, and from TEM-20 to
TEM-52 and (ii) from TEM-1 to TEM-116. Therefore, more
prudent use of these antibiotics is necessary to reduce the
spread of these resistant strains.
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TABLE 3. Amino acid substitutions of TEM-116 and related TEM-type beta-lactamases
Beta-lactamase pI
Residue (coding triplet) at amino acid:
84 104 182 184 238
TEM-1 5.4 Val (GTT) Glu (GAG) Met (ATG) Ala (GCA) Gly (GGT)
TEM-19 5.4 Ser (AGT)
TEM-20 5.4 Thr (ATG) Ser (AGT)
TEM-52 5.9 Lys (AAG) Thr (ACG) Ser (AGT)
TEM-116 5.4 Ile (ATT) Val (GTA)
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